Sannes buying Cannabis

__________________________

📍 Verified store!

📍 Guarantees! Quality! Reviews!

__________________________

▼▼ ▼▼ ▼▼ ▼▼ ▼▼ ▼▼ ▼▼

▲▲ ▲▲ ▲▲ ▲▲ ▲▲ ▲▲ ▲▲

Sannes buying Cannabis

Good Things Coming expands to meet a broader consumer base adding concentrates, pre-rolls, and cartridges, to its product categories. Designed to meet a broader consumer base, the revitalized Good Things Coming portfolio includes concentrates, pre-rolls, and cartridges, in addition to its award-winning edibles. The new products are now available at Sol Flower and select dispensaries throughout Arizona. Grand Cannabis Co. According to market research firm BDSA, 43 percent of adults in fully legal states are cannabis consumers with consumption methods and usage reasons varying greatly across product categories. The bold Good Things Coming rebrand conveys an elevated cannabis experience for the diverse consumer and reflects recent CPG design trends. Featuring eye-catching hues and a sophisticated black color scheme, the modern look is reinforced with a complementary website, GoodThingsComing. The Good Things Coming refresh is also a response to new industry insights. In a recent BDSA report, brand loyalty is projected to emerge as more brands achieve cross border market share with 20 percent of cannabis consumers saying brand reputation influences their product choice. Copperstate Farms is the parent company to multiple product suites including Good Things Coming and dispensary brand Sol Flower, operating five retail locations in Phoenix, Scottsdale, Sun City, and two in Tempe. Copperstate Farms is also home to a acre glass greenhouse in Snowflake, Arizona, with an additional 40 acres approved for cultivation buildout. For more information, visit CopperstateFarms. The company manages the licensed production and distribution of cannabis in the U. Copperstate Farms is dedicated to bringing growth to the local and state economy through the hiring of local laborers, material suppliers, and contractors. About Good Things Coming: Established in , Good Things Coming is a next level cannabis brand with a portfolio of products designed for the diverse cannabis consumer. Handcrafted from sungrown flower in Snowflake, Arizona, Good Things Coming offers precision-dosed products across multiple categories, including live resin cartridges, live resin and live rosin concentrates, pre-rolls, as well as lavender lemon drop and brownie bite edibles. For more information, visit GoodThingsComing. Selected edition. Sign in. My Portfolio News Latest News. Stocks: Most Actives. Credit Cards. Latest News. Copperstate Farms. Tue, Feb 15, , PM 4 min read. Good Things Coming expands to meet a broader consumer base adding concentrates, pre-rolls, and cartridges, to its product categories Good Things Coming product family, Story Continues. Privacy Policy.

Yahoo Finance

Sannes buying Cannabis

Official websites use. Share sensitive information only on official, secure websites. Correspondence , Manan M. A minority of oncologists feel qualified to advise adults with cancer on issues pertaining to medicinal cannabis. We explored dispensary personnel's views and experiences regarding oncologic cannabis and the counsel they extend individuals with cancer. These informed assertions suggest that members of the oncologic community should grapple with the extent to which they feel comfortable with both the nature and degree of counsel adults with cancer receive through dispensaries. Keywords: cannabis, complimentary therapies, dispensary personnel, medical oncology. Medicinal cannabis is legal in 38 states and the District of Columbia. Written consent was waived; however, elements of consent were reviewed. Investigators IMB, MMN, and PRC debriefed after the first five interviews and further refined the guide, namely including probes about varying state laws and their impacts on product availability. Based on debriefs with the research team after every few interviews, interviews ceased after no new emergent themes surfaced i. A coding tree using interview guide domains provided an initial baseline framework. An inductive open coding approach was applied and emergent concepts added to the codebook. At the conclusion of coding, the study team discussed all themes to ensure consistency between data and findings. For these analyses, search terms from the transcribed interview data included: cancer, tumor, oncologist, oncology, chemotherapy, chemo, and Rick Simpson. Methodology is additionally explained elsewhere. Mean number of years in the cannabis industry was 5. Table 1 reports participant demographics and Table 2 exemplar quotations. Interviews commenced with dispensary personnel describing indications for clients medicating with cannabis. Almost a third of participants described cancer as a very common reason e. Interviewees reported that individuals with cancer turn to cannabis for four overarching reasons: 1 physical symptoms, 2 mental health symptoms, 3 disease modifying therapy, and 4 general wellbeing e. Mental health symptoms comprised anxiety e. As an example of such themes, one participant described:. For cancer patients, of course, appetite is a big one. Anxiety… anticipatory anxiety and nausea… neuropathy… sleep… We do have people who… think that it's a cancer cure. By contrast, there was little consensus among participants regarding the antineoplastic properties of cannabinoids. A few who considered cannabis to be anecdotally antineoplastic did not believe it the purview of dispensary staff to recommend cannabis for this indication. A couple noted cannabis to cause fewer adverse effects than prescription opioid medications, chiefly because cannabis was viewed to be less obtunding. For instance, one dispensary employee commented:. Okay, well, automatically, you must need this, this, and that because this is probably your symptoms. Interviewees cited edibles e. For instance:. However, an emergent theme was of individuals with cancer preferring to avoid inhalation. One participant articulated a multimodal approach:. A couple of puffs of your vape pen and then in about a half hour after… eat an edible. And the edible is going to kick in after… as your vape oil cartridge or your concentrate is going to start wearing off. So what you're doing is you're extending the relief; you're layering one on top of the other. There was little consensus around which active ingredients to favor for individuals with cancer. People that were already using cannabis or accepting of cannabis, then they want to have more intoxicated feeling. But for the ones that are going through treatment, don't know what else to do, they don't have any other options, their doctor said that they should try cannabis, that's when I would go with more CBD. Because if they're not used to that intoxicated feel, then it could really turn them off to getting the medicinal benefits. Several challenges inherent in serving an oncologic population emerged in the interviews. First, dispensary personnel sometimes found it difficult to identify clients at the dispensary counter as having cancer:. Not all of our patients are upfront and disclose all of their ailments… I'm sure I've helped a lot of cancer patients but they just don't necessarily say it. You start with a very tiny bit of cannabis, a very light dose, and you move up to a very high dose. It's very heartbreaking when… a cancer patient that comes in and they're so weak and fragile and they need it, but they're not working like they used to have the money to buy enough of it. So you kinda have to… come up with some kind of plan for them to be able to get it and let them know the directions and how to take it and what to take so they won't spend as much money. With the pandemic… we haven't been getting as much product as we used to. And for example, with the \[Rick Simpson Oil\]. I have one lady that I talk to five days a week that purchases the max amount of \[Rick Simpson Oil\] daily because she's going through cancer treatment and she's found that it's helped her so much. For instance, participants reported:. The biggest thing that's lacking in the industry is evidence for me to say… you have cancer, this is what you need to use. This paper represents one of the scientific community's first glimpses into dispensary staff views and advising practices around oncologic medical cannabis. There was little consensus as to ratios of active ingredients optimal for adults with cancer. The impressions and recommendations of dispensary personnel in this study seemed to mirror those of United States oncologists. At the same time, a powerful theme through the transcripts was the degree to which dispensary staff, who are not uniformly trained, function in an almost clinical fashion: gathering history; recommending product formulations, ratios of active ingredients, route s of administration, and dosing schedules; and evolving those plans longitudinally based on client feedback. For clinicians for whom this is a consideration, there may be impetus to increase involvement in guiding clinical conversations around oncologic cannabis. As two examples for possible concern: nearly absent from the transcripts was mention of drug—botanical interactions, and dispensary personnel in this study acknowledged that they are unlikely to have complete knowledge of diagnoses and concomitant medications given how the oncologic cannabis system is set up. Data from this study also begin to suggest manners in which the oncologic cannabis system could be strengthened. First, insurance coverage for cannabis therapy would facilitate dosing consistency which may currently be cost prohibitive for some individuals with cancer. Second, formal dispensary guidelines for identifying and serving adults with cancer could serve to standardize an oncologic approach. Third, increased information transfer between medical facilities, which possess knowledge of diagnoses and concomitant medications, and dispensary storefronts, with grasp of the cannabis formulation and advice given, may improve the feedback loop for oncologic cannabis. Our study has limitations. Its small convenience sample was vulnerable to selection bias. Potential bias could also have been introduced through use of multiple interviewers. Even in the face of these limitation, we believe that our diverse geographic, political, and regulatory sampling strengthened our informed assertions. Understanding the advice given at the dispensary counter seems quite germane and stands to influence clinical care in this domain. Manan M. Nayak: Conceptualization equal ; data curation lead ; formal analysis equal ; investigation equal ; methodology equal ; project administration equal ; software equal ; supervision equal ; writing — original draft equal ; writing — review and editing equal. Peter R. Chai: Data curation equal ; investigation equal ; methodology equal ; writing — original draft supporting ; writing — review and editing supporting. Stephanie Tung: Writing — original draft supporting ; writing — review and editing supporting. James A. Tulsky: Writing — original draft supporting ; writing — review and editing supporting. Marilyn J. Hammer: Writing — original draft supporting ; writing — review and editing supporting. Nicole Andrade: Writing — review and editing supporting. Ilana Braun: Conceptualization lead ; data curation equal ; formal analysis equal ; funding acquisition lead ; investigation equal ; methodology equal ; project administration equal ; resources equal ; software equal ; supervision equal ; writing — original draft equal ; writing — review and editing equal. Ilana Braun participated in a bench research project funded through a structured research agreement between Cannex Scientific and the Brigham and Women's Hospital. For all other authors there are no other conflict of interest. Dispensary personnel's views and experiences regarding oncologic cannabis and the counsel they offer adults with cancer. Cancer Med. The data that support the findings of this study are available from the corresponding author upon reasonable request. This section collects any data citations, data availability statements, or supplementary materials included in this article. As a library, NLM provides access to scientific literature. Find articles by Manan M Nayak. Find articles by Peter R Chai. Find articles by Stephanie Tung. Find articles by James A Tulsky. Marilyn Hammer 2 Phyllis F. Find articles by Marilyn Hammer. Find articles by Nicole Andrade. Find articles by Ilana M Braun. Open in a new tab. It was like night and day. So, then, these are people that were struggling, weren't able to get back out into society. Um, and then just by having this \[cannabis\] treating their symptoms, they were able to get things under control. You know, the example of like, cancer patients? So that's pretty amazing. So there's a study in Spain that showed the tumor shrinkage info, and I think it's been replicated, but none of us are out there saying cannabis is shrinking tumors. Or even, for example, when you're looking at using cannabis oil for a cancer therapy protocol — which is something we do not talk about at the shop. When people ask me about that, I refer them to people who are doing the research and the protocols because it's irresponsible for us to even have that conversation… When you're going into Rick Simpson and he's saying start with the size of a grain of rice — half a grain of rice and get up to a gram a day, well, you could possibly be overflooding your endocannabinoid system. If they were about product \[consumption\], how to \[consume\] it, anything that didn't cross the line of should I \[consume\] this because I have cancer, or will this help my cancer? So, again, a lot of what we target is the symptoms specifically. And most edibles do not really have a terpene profile because once they get to a certain heating point, they burn off. And I'm not percent sure between the quickness. I feel like sublingual, it'll — it goes straight into your bloodstream so much faster, I feel like, than an edible would. But it's actually really good for helping with pain, getting you eating. And one of the things that I see a lot when I work with physicians and nurses or when they recommend people come see me is that they're recommending CBD. And I was able to dissect it based off of his plan and then some of the companies that make \[Rick Simpson Oil\] in town based off of their notes and their plan, and I kind of put both plans together. And it made a little scenario for somebody that's never \[consumed\] cannabis to \[consume\] it responsibly so they don't feel uncomfortable. Similar articles. Add to Collections. Create a new collection. Add to an existing collection. Choose a collection Unable to load your collection due to an error Please try again. Add Cancel. Did not wish to report. Common reasons adults with cancer medicate with cannabis. General principals in counseling adults with cancer. Identifying clients with cancer at the dispensary counter.

Sannes buying Cannabis